300 related articles for article (PubMed ID: 15351351)
1. Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
Van Bambeke F
Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351
[TBL] [Abstract][Full Text] [Related]
2. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
3. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
4. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin resistance: are there better glycopeptides coming?
Linden PK
Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
[TBL] [Abstract][Full Text] [Related]
6. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
Van Bambeke F
Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.
Zhanel GG; Trapp S; Gin AS; DeCorby M; Lagacé-Wiens PR; Rubinstein E; Hoban DJ; Karlowsky JA
Expert Rev Anti Infect Ther; 2008 Feb; 6(1):67-81. PubMed ID: 18251665
[TBL] [Abstract][Full Text] [Related]
8. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Van Bambeke F
Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
[TBL] [Abstract][Full Text] [Related]
9. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
Das B; Sarkar C; Schachter J
Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
[TBL] [Abstract][Full Text] [Related]
10. Review: dalbavancin--a novel lipoglycopeptide antimicrobial for gram positive pathogens.
Das B; Sarkar C; Biswas R; Pandey S
Pak J Pharm Sci; 2008 Jan; 21(1):78-87. PubMed ID: 18166524
[TBL] [Abstract][Full Text] [Related]
11. Oritavancin: a new avenue for resistant Gram-positive bacteria.
Mercier RC; Hrebickova L
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin: a new option for the treatment of gram-positive infections.
Lin SW; Carver PL; DePestel DD
Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
[TBL] [Abstract][Full Text] [Related]
13. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin: a review for dermatologists.
Scheinfeld N
Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
16. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
Arhin FF; Seguin DL; Belley A; Moeck G
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
[TBL] [Abstract][Full Text] [Related]
17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
18. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
Streit JM; Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2004 Feb; 48(2):137-43. PubMed ID: 14972384
[TBL] [Abstract][Full Text] [Related]
19. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
Chang MH; Kish TD; Fung HB
Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.
Arhin FF; Moeck G; Draghi DC; Pillar CM; Sahm DF
Int J Antimicrob Agents; 2010 Nov; 36(5):474-6. PubMed ID: 20846829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
